Furthermore, METTL3-mediated m6A modification was shown to promote stemness maintenance and radioresistance in glioma stem cells (GSCs), highlighting METTL3 as a promising therapeutic target in glioblastomas (GBMs) [30]. The gene discussed is METTL3; the disease is glioma.